Shattuck Labs, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
500 W. 5TH STREET, AUSTIN, TX, 78701
Mailing Address
500 W. 5TH STREET, AUSTIN, TX, 78701
Phone
512-900-4690
Fiscal Year End
1231
EIN
812575858
Financial Overview
FY2025
$11.42M
Total Liabilities
$144.71M
Stockholders' Equity
$-0.70
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | April 8, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
| 8-K Current report of material events | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 22, 2026 | View on SEC |
Annual Reports
10-K
March 5, 2026
- Pioneering immunotherapies with unique Agonist Redirected Checkpoint (ARC®) platform for cancer and autoimmune diseases.
- Lead candidate SL-172154 showed encouraging safety and early effectiveness in Phase 1b clinical trials across several cancer types.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.